Browsing Tag
ChemoSeed
1 post
CRISM Therapeutics (AIM: CRTX) starts ChemoSeed recruitment as first dosing nears
The first clinical site is active and screening can begin, but the immediate Part 1 cohort contains only 12 recurrent glioblastoma patients before the programme expands into a 135-patient randomised efficacy stage.